Leerink Partners raises Genmab stock price target to $32 from $29

Leerink Partners raised its price target on Genmab (GMAB) to $32 from $29, reiterating an Outperform rating, following positive updated Rina-S data presented at ASCO, which showed a 50% objective response rate in endometrial cancer trials. The updated data supports Genmab's plan to initiate a Phase III trial later this year, reinforcing confidence in the company's strategic direction, despite RBC Capital Markets lowering its price target from DKK2,300 to DKK2,000 due to foreign exchange impacts.

Analysis

Leerink Partners has upgraded Genmab A/S's (NASDAQ: GMAB) price target to $32 from $29, maintaining an Outperform rating, driven by impressive updated Rina-S data presented at the ASCO Annual Meeting for second-line and endometrial cancer treatments. This data, which includes a notable 50% objective response rate (ORR) at the 100 mg/m2 dose for endometrial cancer compared to 38% for a higher dose, supports the company's strategy to initiate a Phase III trial later this year and highlights Rina-S's potential in addressing unmet needs. Genmab's financial position appears robust, with an InvestingPro "GREAT" financial health score, a 95% gross profit margin, and 25% revenue growth over the last twelve months, with analyst price targets for GMAB ranging from $20 to $45. Other analysts also weigh in: RBC Capital Markets, while maintaining an Outperform rating, lowered its DKK-denominated price target from DKK2,300 to DKK2,000, attributing the adjustment to foreign exchange impacts. Deutsche Bank also maintained a Buy rating, adjusting its price target to DKK17.50, citing recent Rina-S updates as a positive development. Genmab is also actively managing its capital through an updated share buyback program, alongside routine capital increases from employee warrant exercises.

Key Decisions for Investors

• Given the promising clinical advancements for Rina-S, particularly the strong 50% ORR in endometrial cancer and progression to Phase III trials, investors should closely monitor upcoming trial results and regulatory milestones as key catalysts for Genmab.
• The company's strong financial metrics, including a 95% gross profit margin and 25% recent revenue growth, coupled with an ongoing share buyback program, provide a solid fundamental underpinning, although the dilutive effect of employee warrant exercises should be considered.
• Investors should consider the overall positive analyst sentiment, reflected in maintained Outperform and Buy ratings, while also being mindful of price target variations and specific factors influencing them, such as the foreign exchange impacts cited by RBC.